Cargando…

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?

The therapeutic landscape for patients with non-small cell lung cancer (NSCLC) has dramatically evolved with the development and adoption of immune checkpoint inhibitors (ICI) as front-line therapy. These novel antibodies target the interactions in immunoregulatory pathways, between programmed death...

Descripción completa

Detalles Bibliográficos
Autores principales:	Britt, Alec S., Huang, Caitlyn, Huang, Chao H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745068/ https://www.ncbi.nlm.nih.gov/pubmed/36523973 http://dx.doi.org/10.3389/fonc.2022.996554

Ejemplares similares

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Choi, Yong Jun, et al.
Publicado: (2020)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Zulato, Elisabetta, et al.
Publicado: (2022)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
por: Kim, Jehun, et al.
Publicado: (2022)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
por: Liu, Xiaojun, et al.
Publicado: (2022)

Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?
por: Pourmir, Ivan, et al.
Publicado: (2020)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report
por: Qing, Defeng, et al.
Publicado: (2021)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report
por: Dong, Shixia, et al.
Publicado: (2022)

Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region
por: Nieder, Carsten, et al.
Publicado: (2020)

The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small Cell Lung Cancer: A Meta-Analysis
por: Li, Sihan, et al.
Publicado: (2021)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qqk2hliknkt4q4j9th3lh004d3